Barinthus Biotherapeutics plc Total Liabilities
Barinthus Biotherapeutics plc total liabilities. Based on the latest financial reports, Barinthus Biotherapeutics plc (BRNS) has total liabilities worth $24.64 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See Barinthus Biotherapeutics plc (BRNS) defensive interval to measure how many days the company can operate on defensive assets alone.
Total Liabilities of Barinthus Biotherapeutics plc (2019–2024)
Total liabilities of Barinthus Biotherapeutics plc from 2019 to 2024. This chart illustrates how Barinthus Biotherapeutics plc's total liabilities have evolved over time, based on quarterly financial data.
Barinthus Biotherapeutics plc Competitors by Total Liabilities
The table below lists competitors of Barinthus Biotherapeutics plc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Eastern Commercial Leasing Public Company Limited
BK:ECL
|
Thailand | ฿3.14 Billion |
|
Centric Holdings S.A
AT:CENTR
|
Greece | €11.16 Million |
|
FreeMs Corporation
KQ:053160
|
Korea | ₩8.99 Billion |
|
ENERGIA IN.Y DES. EO 025
F:F63
|
Germany | €119.79 Million |
|
WIIK Public Company Limited
BK:WIIK
|
Thailand | ฿833.60 Million |
|
Kein Hing International Bhd
KLSE:7199
|
Malaysia | RM79.58 Million |
|
Serinus Energy Inc.
WAR:SEN
|
Poland | zł50.04 Million |
|
P-Two Industries
TWO:6158
|
Taiwan | NT$1.23 Billion |
Liability Composition Analysis (2019–2024)
This chart breaks down Barinthus Biotherapeutics plc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see BRNS total asset value.
Liquidity & Leverage Metrics
Barinthus Biotherapeutics plc Total Liabilities Ratios Explained
Barinthus Biotherapeutics plc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 8.04 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.29 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.23 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Barinthus Biotherapeutics plc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Barinthus Biotherapeutics plc (2019–2024)
The table below shows the annual total liabilities of Barinthus Biotherapeutics plc from 2019 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $30.19 Million | +9.75% |
| 2023-12-31 | $27.51 Million | +1.88% |
| 2022-12-31 | $27.00 Million | -4.08% |
| 2021-12-31 | $28.15 Million | -47.68% |
| 2020-12-31 | $53.81 Million | +30.86% |
| 2019-12-31 | $41.12 Million | -- |
About Barinthus Biotherapeutics plc
Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, focuses on developing immunotherapeutic drug candidates for treating auto-immune and inflammatory diseases. Its lead candidate is VTP-1000, which is in Phase 1 clinical trial to restore immune non-responsiveness to gluten in patients with celiac disease. The company is also developing VTP-300, an immunotherapeutic targetin… Read more